42.33
0.57%
0.24
アフターアワーズ:
42.33
前日終値:
$42.09
開ける:
$42.22
24時間の取引高:
947.97K
Relative Volume:
0.84
時価総額:
$9.41B
収益:
$1.94B
当期純損益:
$72.70M
株価収益率:
29.19
EPS:
1.45
ネットキャッシュフロー:
$405.21M
1週間 パフォーマンス:
+0.57%
1か月 パフォーマンス:
+0.50%
6か月 パフォーマンス:
-5.98%
1年 パフォーマンス:
+1.73%
Qiagen Nv Stock (QGEN) Company Profile
QGEN を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
QGEN | 42.33 | 9.41B | 1.94B | 72.70M | 405.21M | 1.45 |
TMO | 516.10 | 196.16B | 42.37B | 6.14B | 7.78B | 15.26 |
DHR | 235.05 | 167.17B | 23.74B | 3.89B | 4.98B | 7.93 |
A | 132.06 | 37.94B | 6.50B | 1.41B | 1.42B | 3.82 |
IQV | 197.60 | 35.86B | 15.32B | 1.41B | 1.96B | 5.95 |
IDXX | 418.55 | 34.27B | 3.84B | 866.24M | 792.60M | 9.80 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2023-12-19 | 開始されました | Wells Fargo | Equal Weight |
2023-12-13 | 開始されました | Wolfe Research | Peer Perform |
2023-12-07 | アップグレード | Goldman | Neutral → Buy |
2023-09-12 | 開始されました | Robert W. Baird | Outperform |
2023-05-23 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2022-10-18 | 開始されました | Morgan Stanley | Equal-Weight |
2022-01-18 | アップグレード | DZ Bank | Hold → Buy |
2021-10-15 | 再開されました | Cowen | Market Perform |
2021-10-14 | 開始されました | Redburn | Buy |
2021-07-14 | ダウングレード | Kepler | Buy → Hold |
2021-06-03 | 開始されました | Goldman | Neutral |
2020-10-06 | 再開されました | BofA Securities | Buy |
2020-09-28 | アップグレード | Kepler | Hold → Buy |
2020-08-24 | アップグレード | Citigroup | Neutral → Buy |
2020-08-20 | 再開されました | JP Morgan | Overweight |
2020-08-17 | アップグレード | Berenberg | Hold → Buy |
2020-08-14 | アップグレード | Deutsche Bank | Hold → Buy |
2020-08-14 | アップグレード | Exane BNP Paribas | Neutral → Outperform |
2020-03-04 | ダウングレード | Berenberg | Buy → Hold |
2020-01-08 | 開始されました | Wells Fargo | Equal Weight |
2020-01-07 | 開始されました | Citigroup | Neutral |
2019-12-26 | 再開されました | BofA/Merrill | Underperform |
2019-11-15 | 開始されました | Stifel | Hold |
2019-11-14 | アップグレード | Evercore ISI | In-line → Outperform |
2019-11-14 | アップグレード | JP Morgan | Underweight → Overweight |
2019-11-14 | アップグレード | Kepler | Reduce → Hold |
2019-10-17 | アップグレード | Wolfe Research | Peer Perform → Outperform |
2019-10-09 | ダウングレード | Kepler | Hold → Reduce |
2019-10-08 | ダウングレード | Barclays | Overweight → Equal Weight |
2019-10-08 | ダウングレード | Deutsche Bank | Buy → Hold |
2019-10-08 | ダウングレード | JP Morgan | Neutral → Underweight |
すべてを表示
Qiagen Nv (QGEN) 最新ニュース
Massachusetts Financial Services Co. MA Sells 79,145 Shares of Qiagen (NYSE:QGEN) - MarketBeat
Jennison Associates LLC Boosts Position in Qiagen (NYSE:QGEN) - MarketBeat
QIAGEN NV : Jefferies is Neutral - Marketscreener.com
Qiagen (NYSE:QGEN) Stake Lowered by Nuance Investments LLC - MarketBeat
QIAGEN Stock Flat Post Q3 Earnings & Revenue Beat, 2024 EPS View Up - MSN
Qiagen (NYSE:QGEN) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Qiagen (NYSE:QGEN) Shares Bought by Natixis Advisors LLC - MarketBeat
180,729 Shares in Qiagen (NYSE:QGEN) Purchased by Impax Asset Management Group plc - MarketBeat
QGEN Collaborates With McGill University Centre: Stock to Gain? - Yahoo Finance
Victory Capital Management Inc. Has $117.33 Million Stock Position in Qiagen (NYSE:QGEN) - MarketBeat
What is William Blair's Estimate for Qiagen FY2024 Earnings? - MarketBeat
Crossmark Global Holdings Inc. Sells 12,133 Shares of Qiagen (NYSE:QGEN) - MarketBeat
Pharmahungary Group participates in ambitious EU EVEREST Project - European Biotechnology News
QIAGEN collaborates with McGill University to advance microbiome research - GlobeNewswire
QIAGEN Partners with McGill to Target $1.8B Microbiome Market in Major Research Deal | QGEN Stock News - StockTitan
Don't Overlook Qiagen (QGEN) International Revenue Trends While Assessing the Stock - Yahoo Finance
QIAGEN NV : UBS reiterates its Neutral rating - Marketscreener.com
Earnings call: QIAGEN tops Q3 expectations, raises 2024 EPS outlook - Investing.com India
Earnings call: QIAGEN tops Q3 expectations, raises 2024 EPS outlook By Investing.com - Investing.com Australia
Qiagen Non-GAAP EPS of $0.46 beats by $0.02, revenue of $459M beats by $2.09M - MSN
Wellington Management Group LLP's Strategic Acquisition of Qiage - GuruFocus.com
Why Qiagen (QGEN) is a Top Value Stock for the Long-Term - Yahoo Finance
Qiagen NV (QGEN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements - GuruFocus.com
Qiagen Reports Strong Q3 2024 Growth - TipRanks
Is There An Opportunity With Qiagen N.V.'s (NYSE:QGEN) 31% Undervaluation? - Yahoo Finance
QIAGEN NV : Deutsche Bank reaffirms its Buy rating - Marketscreener.com
Qiagen Q3 24 Earnings Conference Call At 9:30 AM ET - Nasdaq
QIAGEN : Markets hailed the Q3 beat + the profitability upgrade - Marketscreener.com
QIAGEN NV : Receives a Buy rating from Berenberg - Marketscreener.com
Qiagen (NYSE:QGEN) Shares Sold by Van ECK Associates Corp - MarketBeat
Qiagen N : QIAGEN delivers solid Q3 2024 growth ahead of outlook, increases full year 2024 adjusted EPS outlook - Marketscreener.com
QIAGEN NV : UBS reaffirms its Neutral rating - Marketscreener.com
Qiagen N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Compared to Estimates, Qiagen (QGEN) Q3 Earnings: A Look at Key Metrics - Yahoo Finance
Qiagen (QGEN) Q3 Earnings and Revenues Top Estimates - Yahoo Finance
Diagnostics firm Qiagen reports rise in third-quarter revenue - Reuters
QIAGEN delivers solid Q3 2024 growth ahead of outlook, increases full-year 2024 adjusted EPS outlook - The Manila Times
QIAGEN Q3 Earnings Surge: Sales Hit $502M, Boosts 2024 EPS Outlook | QGEN Stock News - StockTitan
Qiagen NV (QGEN) Q3 2024: Everything You Need to Know Ahead of E - GuruFocus.com
FDA clears fourth Qiagen test in 2024 - BioWorld Online
Qiagen NV (QGEN) Q3 2024 Earnings Report Preview: What to Expect - GuruFocus.com
QGEN Stock Set to Gain From FDA's Clearance of QIAstat-Dx Mini Panel - Yahoo Finance
Qiagen (QGEN) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates - Yahoo Finance
QIAGEN receives FDA clearance of QIAstat-Dx meningitis/encephalitis panel to support emergency diagnostics - GlobeNewswire
Qiagen Receives FDA Clearance Of Qiastat-Dx Meningitis/Encephalitis Panel To Support Emergency Diagnostics - XM
Forsta AP Fonden Sells 18,586 Shares of Qiagen (NYSE:QGEN) - MarketBeat
Qiagen (QGEN) Set to Announce Earnings on Wednesday - MarketBeat
Raymond James & Associates Trims Position in Qiagen (NYSE:QGEN) - MarketBeat
Global Exosome Market to Surge at a Tremendous CAGR of ~20% by 2030 | DelveInsight - GlobeNewswire Inc.
QIAGEN receives FDA clearance for QIAstat-Dx mini panel to improve precision in outpatient respiratory treatment - Yahoo Finance
Qiagen Nv (QGEN) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):